There is no FDA-approved generic version of semaglutide. What most people call “generic semaglutide” is actually a compounded version, mixed by specialty pharmacies rather than manufactured by the brand-name drugmaker. Compounded semaglutide does produce weight loss, but the results are slightly less impressive than the brand-name drug, and the legal landscape around these products shifted dramatically in early 2025.
What “Generic Semaglutide” Actually Is
Semaglutide is the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for weight loss). No pharmaceutical company has received FDA approval to sell a true generic equivalent of either drug. The products advertised as generic or low-cost semaglutide are compounded versions, meaning a pharmacy mixes the drug from bulk ingredients rather than repackaging a manufacturer’s product.
Compounding pharmacies were legally permitted to make semaglutide copies while the drug was on the FDA’s official shortage list, which it was from 2022 through early 2025. In February 2025, the FDA declared that shortage resolved. By late April 2025, the enforcement grace period for compounders ended, meaning pharmacies can no longer legally produce products that are essentially copies of FDA-approved semaglutide.
How Compounded Semaglutide Compares on Weight Loss
A real-world study of nearly 2,800 patients in a digital weight loss program compared compounded semaglutide to brand-name semaglutide over four months. Both groups also received health coaching. Patients on the brand-name version lost an average of 9.87% of their body weight, while those on the compounded version lost 9.11%. That difference, while statistically measurable, is relatively small in practical terms.
Where the gap widened was at higher weight loss thresholds. About 81% of patients in both groups hit the 5% weight loss mark, which is generally considered clinically meaningful. But 50% of brand-name patients lost at least 10% of their body weight compared to 45% of those on compounded semaglutide. The difference was even more pronounced at the 15% threshold: 21% of brand-name patients reached it versus just 13% on compounded versions.
Interestingly, patients on compounded semaglutide reported slightly fewer side effects than those on the brand-name drug. This could reflect differences in absorption, potency, or formulation, but it also likely explains the slightly lower weight loss, since the drug’s side effects (nausea, reduced appetite) are closely tied to its mechanism of action.
The Salt Form Problem
One of the FDA’s biggest concerns with compounded semaglutide is that some pharmacies use a chemically different form of the drug. Brand-name Ozempic and Wegovy use the base form of semaglutide. Some compounders instead use salt forms, such as semaglutide sodium or semaglutide acetate. These are technically different active ingredients. The FDA has stated it has no information about whether these salt forms behave the same way in the body, and it does not consider there to be a lawful basis for using them in compounding.
This matters because salt forms can affect how a drug is absorbed, how potent it is at a given dose, and how it interacts with the body. If you’ve used a compounded product and found it less effective or had unexpected side effects, the salt form could be a factor. There is no simple way for a consumer to verify which form a compounder used.
Dosing Risks With Compounded Versions
Brand-name semaglutide comes in pre-filled pens with fixed dose settings, making it difficult to inject the wrong amount. Compounded semaglutide typically comes in vials, requiring you to draw up the dose yourself with a syringe. The FDA has issued alerts about dosing errors with compounded injectable semaglutide products. Too high a dose can cause severe nausea, vomiting, and dangerously low blood sugar, while too low a dose simply won’t work as well.
What Brand-Name Semaglutide Costs Now
Cost was the main reason people turned to compounded semaglutide, but brand-name pricing has dropped significantly. Novo Nordisk, the maker of Wegovy and Ozempic, now offers self-pay pricing that makes the brand-name drug more accessible than it was even a year ago. New patients paying cash can get the starting doses of Wegovy injections for $199 per month, or Wegovy oral tablets for $149 per month. After the first two months, and at higher doses, the price rises to $299 to $349 per month for injections and $349 for tablets. Ozempic starts at $199 per month for new cash-pay patients, then increases to $349 or $499 depending on the dose.
These prices are still substantial, but they’re far lower than the $1,000-plus list prices that drove the compounding boom. If you previously chose compounded semaglutide purely on cost, it’s worth rechecking brand-name pricing.
Counterfeit Products Are a Separate Risk
Beyond compounded versions, outright counterfeit Ozempic pens have entered the U.S. supply chain. The FDA has flagged multiple fake lot numbers, including products where the pen labels, patient information, and even the needles were counterfeit. Because the sterility of counterfeit needles can’t be confirmed, using them raises infection risk on top of questions about whether the drug inside is real.
You can spot some counterfeits by checking the label layout. On authentic Ozempic pens, the text “EXP/LOT” appears above the expiration date and lot number. On known counterfeits, that text appears to the left instead. If anything about your pen looks different from what you’ve received before, or if you purchased it from an unverified online source, do not use it. Novo Nordisk’s customer line (1-800-727-6500) can help verify whether a specific product is legitimate.
The Bottom Line on Effectiveness
Compounded semaglutide does produce real weight loss, and for many people the results were close to the brand-name drug. But “close” came with trade-offs: less regulatory oversight, potential use of unverified salt forms, dosing complexity, and slightly lower results at higher weight loss targets. With the FDA shortage now resolved and enforcement discretion for compounders expired, the legal supply of compounded semaglutide is shrinking. Any compounded semaglutide product you encounter going forward exists in a murkier regulatory space than it did a year ago, and the brand-name versions are more affordable than they’ve ever been.